查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2026881

癌症切片檢查市場預測至2034年—按產品、類型、應用、最終用戶和地區分類的全球分析

Cancer Biopsy Market Forecasts to 2034 - Global Analysis By, Product (Instruments, Kits and Consumables and Other Products), Type (Tissue Biopsies, Liquid Biopsies, Surgical Biopsies and Other Types), Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球癌症切片檢查市場規模將達到 460 億美元，並在預測期內以 20% 的複合年成長率成長，到 2034 年將達到 1976 億美元。

癌症切片檢查是一種醫療程序，透過從疑似或異常腫瘤、腫塊或病灶處取一小塊組織樣本進行檢查，以確定是否存在癌細胞、癌細胞的性質和特徵。癌症切片檢查為腫瘤科醫生和其他醫療保健專業人員提供準確詳細的信息，有助於做出準確診斷，並根據每位患者癌症的獨特特徵制定個性化的治療方案。

根據美國乳癌統計數據，美國大約八分之一的女性會罹患侵襲性乳癌。

癌症發生率上升

癌症仍然是全球性的健康問題，由於老化、生活方式改變、環境暴露和遺傳易感性等多種因素的影響，各類癌症的診斷人數不斷增加。隨著癌症患者人數的增加，對準確快速的癌症診斷的需求也日益成長。切片檢查程序透過採集組織樣本進行病理分析，在確診癌症方面發揮至關重要的作用。因此，癌症發生率的上升是推動市場需求成長的關鍵因素。

高成本

高昂的診斷費用是阻礙全球癌症切片檢查市場成長的主要因素之一。癌症診斷測試​​價格極為昂貴，對患者家庭帶來額外的經濟負擔。因此，對於沒有保險的中產階級來說，這些測試難以負擔。此外，許多私人保險公司不承保癌症診斷相關費用，因此高昂的診斷費用限制了癌症篩檢技術的普及應用。

技術進步

技術進步催生了微創切片檢查技術，例如細針穿刺切片檢查(FNA)、粗針穿刺活體組織切片 (CNB) 和內視鏡切片檢查。這些技術採用較小的切口和針頭採集組織樣本，與傳統開放性手術切片檢查相比，可減輕患者不適，降低併發症風險，並加速復原。這些因素正在推動市場需求。

缺乏意識

在某些地區和人群中，公眾和醫療專業人員對切片檢查在癌症診斷中的關鍵作用認知不足。患者可能並不完全了解切片檢查在確定腫瘤性質和特徵方面的重要性，因此，他們可能會猶豫或抗拒接受這些必要的診斷檢查。因此，認知不足是市場成長的主要障礙。

新冠疫情的影響

新冠疫情的爆發對癌症切片檢查市場產生了重大影響。疫情初期，社交距離措施嚴重限制了醫院就診，僅允許急診患者入院，對市場擴張造成了負面影響。此外，疫情後新技術應用增多，為該市場開闢了新的前景。

在預測期內，外科切片檢查部分預計將佔據最大佔有率。

據估計，手術切片檢查佔比最大。手術切片檢查是一種在切開或手術過程中取得組織樣本的技術。當需要較大組織樣本進行詳細檢查時，通常會採用這種方法，以便病理學家分析腫瘤的​​特徵、惡性程度和轉移範圍。在切片檢查中，手術切片檢查常用於位於深部或難以觸及部位的腫瘤。在這些部位，取得足夠的組織樣本對於準確診斷和製定治療方案至關重要。

在預測期內，設備細分市場預計將呈現最高的複合年成長率。

預計在預測期內，醫療器材領域將實現顯著成長。醫療設備在實現精準有效的切片檢查過程中發揮著至關重要的作用，有助於癌症的精確診斷和治療方案製定。這些器械包括用於採集組織樣本進行切片檢查的各種儀器，例如傳統的切片穿刺針和活體組織切片鉗，以及專為微創手術設計的專用儀器。此外，超音波、磁振造影（MRI）和電腦斷層掃描（CT）等先進影像設備在幫助臨床醫生確定切片檢查部位並進行標靶、精準的取樣方面也發揮著不可或缺的作用。

市佔率最大的地區：

在預測期內，亞太地區佔據了最大的市場佔有率，這主要得益於醫療基礎設施的快速發展以及人們對癌症早期檢測和治療日益成長的關注。隨著中國、印度和日本等國家癌症患者人數的不斷增加，作為診斷流程關鍵環節的切片檢查技術的需求也隨之上升。此外，該地區致力於改善癌症治療和推進醫學研究，使其成為全球癌症切片檢查市場的重要貢獻者。

複合年成長率最高的地區：

預計在預測期內，北美地區將保持強勁成長，這主要得益於其先進的醫療基礎設施、較高的癌症發病率以及對技術創新的高度重視。北美地區廣泛應用多種切片檢查技術，包括手術切片檢查、針吸活體組織切片和液態生物檢體，以獲取準確全面的信息，用於癌症診斷和治療方案的製定。此外，該地區採用尖端影像技術、分子診斷和微創切片檢查方法，也體現了其致力於提高診斷準確性和改善患者預後的決心。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球癌症切片檢查市場：依產品分類

  • 裝置
  • 試劑盒和耗材
  • 其他產品

第6章 全球癌症切片檢查市場：按類型分類

  • 組織切片檢查
    • 針刺切片
      • 細針穿刺切片檢查
      • 核心針穿刺切片
    • 手術切片檢查
  • 液態生物檢體
  • 手術切片檢查
  • 其他類型

第7章 全球癌症切片檢查市場：依應用領域分類

  • 子宮頸癌
  • 結腸癌
  • 攝護腺癌
  • 乳癌
  • 肺癌
  • 皮膚癌
  • 腎癌
  • 血癌
  • 卵巢癌
  • 肝癌
  • 胰臟癌
  • 其他用途

第8章 全球癌症切片檢查市場：按最終用戶分類

  • 診斷檢查室
  • 醫院
  • 其他最終用戶

第9章 全球癌症切片檢查市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • Becton, Dickinson and Company
  • Abbott Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Hologic, Inc.
  • NeoGenomics, Inc.
  • Koninklijke Philips NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Sysmex Corporation
Product Code: SMRC24705

According to Stratistics MRC, the Global Cancer Biopsy Market is accounted for $46.0 billion in 2026 and is expected to reach $197.6 billion by 2034 growing at a CAGR of 20% during the forecast period. A cancer biopsy is a medical procedure involving the removal and examination of a small tissue sample from a suspicious or abnormal growth, lump, or lesion to determine the presence, nature, and characteristics of cancer cells. Cancer biopsies are fundamental to providing accurate and detailed information for oncologists and healthcare professionals, helping them formulate precise diagnoses and develop tailored treatment plans based on the unique characteristics of each patient's cancer.

According to USA breast cancer statistics, about one in every eight women in the USA develops invasive breast cancer.

Market Dynamics:

Driver:

Rising cancer incidence

Cancer continues to be a global health concern, with increasing numbers of individuals being diagnosed with various types of cancer due to various factors such as aging populations, lifestyle changes, environmental exposures, and genetic predisposition. As the number of cancer cases increases, the demand for accurate and timely cancer diagnosis also grows. Biopsy procedures play a crucial role in confirming cancer diagnoses by obtaining tissue samples for pathological analysis. Therefore, rising cancer incidence is a significant factor accelerating market demand.

Restraint:

High cost

The high cost of diagnosis is one of the main factors anticipated to impede the growth of the global cancer biopsy market. Cancer diagnostic tests are highly costly, which puts additional financial strain on patient families. Thus, these tests are not affordable for middle-class patient population that is not covered under any insurance. Additionally, a number of private insurance companies do not pay for cancer diagnosis-related expenses, which means that the high cost of diagnosis restricts the use of cancer screening technologies.

Opportunity:

Technological advancements

Technological advancements have led to the development of minimally invasive biopsy techniques such as fine needle aspiration (FNA), core needle biopsy (CNB), and endoscopic biopsy. These techniques use smaller incisions or needles to obtain tissue samples, reducing patient discomfort, minimizing the risk of complications, and enabling faster recovery compared to traditional open surgical biopsies. These factors enhance market demand.

Threat:

Lack of awareness

In certain regions or demographic segments, there is a lack of sufficient awareness among both the general population and healthcare professionals about the critical role of biopsies in cancer diagnosis. Patients may not fully comprehend the importance of biopsy procedures in determining the nature and characteristics of tumours, leading to hesitancy or reluctance to undergo these essential diagnostic tests. As a result, a lack of awareness is a significant restraint hampering the market.

Covid-19 Impact

The emergence of COVID-19 had a significant impact on the cancer biopsy market. Hospital visits were severely restricted during the early stages of the pandemic as a result of social distancing measures; only patients with emergencies were permitted, which had a negative effect on the market's expansion. Moreover, following the pandemic, there was a rise in the adoption of new technologies, which opened up new prospects for the market under study.

The surgical biopsies segment is expected to be the largest during the forecast period

The surgical biopsies segment is estimated to hold the largest share. A surgical biopsy involves the removal of a tissue sample through an incision or during a surgical procedure. This method is commonly employed when larger tissue specimens are needed for thorough examination, allowing pathologists to analyze the tumour's characteristics, grade, and extent of spread. In cancer biopsies, surgical biopsies are frequently utilized for tumours located in deep or challenging-to-access areas, where obtaining an adequate tissue sample is crucial for accurate diagnosis and treatment planning.

The instruments segment is expected to have the highest CAGR during the forecast period

The instruments segment is anticipated to have lucrative growth during the forecast period. Instruments play a pivotal role in facilitating precise and effective biopsy procedures, contributing to accurate cancer diagnoses and treatment decisions. These instruments encompass a wide range of devices used to obtain tissue samples for examination, including traditional biopsy needles, biopsy forceps, and specialized tools designed for minimally invasive procedures. Additionally, advanced imaging instruments such as ultrasound, MRI, and CT scanners are integral to guiding clinicians to the specific site for biopsy, ensuring targeted and accurate sampling.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to rapid advancements in healthcare infrastructure and a growing focus on early cancer detection and treatment. With a rising prevalence of cancer cases in countries like China, India, and Japan, there is an increasing demand for biopsy procedures as a crucial component of the diagnostic pathway. Moreover, the region's commitment to improving cancer care and fostering medical research positions it as a key contributor to the global cancer biopsy market.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to advanced healthcare infrastructure, a high prevalence of cancer cases, and a robust focus on technological innovation. In North America, various biopsy techniques, including surgical, needle, and liquid biopsies, are widely employed to obtain precise and comprehensive information for cancer diagnosis and treatment planning. Additionally, the adoption of cutting-edge imaging technologies, molecular diagnostics, and minimally invasive biopsy procedures underscores the region's commitment to enhancing diagnostic accuracy and patient outcomes.

Key players in the market

Some of the key players in the Cancer Biopsy Market include Becton, Dickinson and Company, Abbott Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Illumina, Inc., Myriad Genetics, Inc., Hologic, Inc., NeoGenomics, Inc., Koninklijke Philips N.V., Siemens Healthineers AG, Thermo Fisher Scientific Inc., QIAGEN N.V. and Sysmex Corporation.

Key Developments:

In May 2023, Partnership between Thermo Fisher Scientific and BRIN to enable and enhance the country's national research and innovation infrastructure and capability.

In March 2023, Thermo Fisher Scientific, the world leader in serving science, and Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage cell therapy company engineering advanced chimeric antigen receptor (CAR)-T cell therapies for solid tumors, announced an update to our strategic collaboration to further the development of manufacturing processes for new cancer treatments.

In Jan 2023, Philips a global leader in health technology, and Masimo, a global medical technology company, announced an expansion of their partnership to augment patient monitoring capabilities in home telehealth applications with the Masimo W1(TM) advanced health tracking watch.

Products Covered:

  • Instruments
  • Kits and Consumables
  • Other Products

Types Covered:

  • Tissue Biopsies
  • Liquid Biopsies
  • Surgical Biopsies
  • Other Types

Applications Covered:

  • Cervical Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Lung Cancer
  • Skin Cancer
  • Kidney Cancer
  • Blood Cancer
  • Ovarian Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Other Applications

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Biopsy Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Kits and Consumables
  • 5.4 Other Products

6 Global Cancer Biopsy Market, By Type

  • 6.1 Introduction
  • 6.2 Tissue Biopsies
    • 6.2.1 Needle Biopsies
      • 6.2.1.1 Fine Needle Aspiration
      • 6.2.1.2 Core Needle Biopsy
    • 6.2.2 Surgical Biopsies
  • 6.3 Liquid Biopsies
  • 6.4 Surgical Biopsies
  • 6.5 Other Types

7 Global Cancer Biopsy Market, By Application

  • 7.1 Introduction
  • 7.2 Cervical Cancer
  • 7.3 Colorectal Cancer
  • 7.4 Prostate Cancer
  • 7.5 Breast Cancer
  • 7.6 Lung Cancer
  • 7.7 Skin Cancer
  • 7.8 Kidney Cancer
  • 7.9 Blood Cancer
  • 7.10 Ovarian Cancer
  • 7.11 Liver Cancer
  • 7.12 Pancreatic Cancer
  • 7.13 Other Applications

8 Global Cancer Biopsy Market, By End User

  • 8.1 Introduction
  • 8.2 Diagnostic Laboratories
  • 8.3 Hospitals
  • 8.4 Other End Users

9 Global Cancer Biopsy Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Becton, Dickinson and Company
  • 11.2 Abbott Laboratories
  • 11.3 Danaher Corporation
  • 11.4 F. Hoffmann-La Roche Ltd.
  • 11.5 Bio-Rad Laboratories, Inc.
  • 11.6 Illumina, Inc.
  • 11.7 Myriad Genetics, Inc.
  • 11.8 Hologic, Inc.
  • 11.9 NeoGenomics, Inc.
  • 11.10 Koninklijke Philips N.V.
  • 11.11 Siemens Healthineers AG
  • 11.12 Thermo Fisher Scientific Inc.
  • 11.13 QIAGEN N.V.
  • 11.14 Sysmex Corporation

List of Tables

  • Table 1 Global Cancer Biopsy Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Cancer Biopsy Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Cancer Biopsy Market Outlook, By Instruments (2023-2034) ($MN)
  • Table 4 Global Cancer Biopsy Market Outlook, By Kits and Consumables (2023-2034) ($MN)
  • Table 5 Global Cancer Biopsy Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 6 Global Cancer Biopsy Market Outlook, By Type (2023-2034) ($MN)
  • Table 7 Global Cancer Biopsy Market Outlook, By Tissue Biopsies (2023-2034) ($MN)
  • Table 8 Global Cancer Biopsy Market Outlook, By Needle Biopsies (2023-2034) ($MN)
  • Table 9 Global Cancer Biopsy Market Outlook, By Surgical Biopsies (2023-2034) ($MN)
  • Table 10 Global Cancer Biopsy Market Outlook, By Liquid Biopsies (2023-2034) ($MN)
  • Table 11 Global Cancer Biopsy Market Outlook, By Surgical Biopsies (2023-2034) ($MN)
  • Table 12 Global Cancer Biopsy Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 13 Global Cancer Biopsy Market Outlook, By Application (2023-2034) ($MN)
  • Table 14 Global Cancer Biopsy Market Outlook, By Cervical Cancer (2023-2034) ($MN)
  • Table 15 Global Cancer Biopsy Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 16 Global Cancer Biopsy Market Outlook, By Prostate Cancer (2023-2034) ($MN)
  • Table 17 Global Cancer Biopsy Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 18 Global Cancer Biopsy Market Outlook, By Lung Cancer (2023-2034) ($MN)
  • Table 19 Global Cancer Biopsy Market Outlook, By Skin Cancer (2023-2034) ($MN)
  • Table 20 Global Cancer Biopsy Market Outlook, By Kidney Cancer (2023-2034) ($MN)
  • Table 21 Global Cancer Biopsy Market Outlook, By Blood Cancer (2023-2034) ($MN)
  • Table 22 Global Cancer Biopsy Market Outlook, By Ovarian Cancer (2023-2034) ($MN)
  • Table 23 Global Cancer Biopsy Market Outlook, By Liver Cancer (2023-2034) ($MN)
  • Table 24 Global Cancer Biopsy Market Outlook, By Pancreatic Cancer (2023-2034) ($MN)
  • Table 25 Global Cancer Biopsy Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 26 Global Cancer Biopsy Market Outlook, By End User (2023-2034) ($MN)
  • Table 27 Global Cancer Biopsy Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 28 Global Cancer Biopsy Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 29 Global Cancer Biopsy Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.